ALXO vs ALZN

ALX Oncology Holdings Inc. vs Alzamend Neuro, Inc. — Valuation Comparison 2026

ALXO

Biotechnology
ALX Oncology Holdings Inc.
Quality
4.9
out of 10
Value Trap
18
SAFE
Price
$1.89
Last close
Models
7/13
Active
VS

ALZN

Biotechnology
Alzamend Neuro, Inc.
Quality
4.1
out of 10
Value Trap
12
SAFE
Price
$1.15
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType ALXO Fair ValueALXO Upside ALZN Fair ValueALZN Upside
Bayesian DCF Intrinsic $0.58 -69.1% $0.70 -39.3%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.82 -56.6% $0.05 -95.4%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ALXO vs ALZN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ALXO vs ALZN — Which Stock Is More Undervalued?

ALXO scores higher with a 4.9/10 quality rating vs ALZN's 4.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing ALX Oncology Holdings Inc. (ALXO) and Alzamend Neuro, Inc. (ALZN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ALXO currently trades at $1.89 with a QOC of 4.9/10, while ALZN trades at $1.15 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).